title: [Long-term outcome after injection sclerotherapy for esophageal variceal bleeding in children with portal hypertension].
abstract: OBJECTIVE
  Endoscopic sclerotherapy has emerged as an effective treatment for bleeding esophageal varices in adults and children but the long-term outcome is poorly defined in children. The present study aimed to study the long-term effect of endoscopic sclerotherapy in children with portal hypertension.
  
  
  METHODS
  Fifteen patients (age 3 to 14 years) with esophageal variceal bleeding underwent endoscopic injection treatments with 1% Aethoxy-sclerol since 1996. All subjects continued to receive the therapy by repeated intra and extravariceal endoscopic sclerotherapy at intervals of 3 - 4 weeks until the varices disappeared, and received regular endoscopic follow-up.
  
  
  RESULTS
  Fifteen patients had totally 43 injections, and were followed up from 40 to 86 months (mean 66 months) by endoscopy. Two patients received 2 injections and 5 received 3 before eradication of varices. The mean time needed for varices eradication was 3 to 6 months. Recurrence of varices and bleeding was seen in 3 patients who had duodenal ulcer.
  
  
  CONCLUSIONS
  Endoscopic sclerotherapy is a safe and effective treatment for pediatric esophageal varices.
authors.affiliation: Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Second Medical University, Shanghai, 200025 China.
authors.forename: Chun-Di
authors.initials: CD
authors.lastname: Xu
authors.forename: Chao-Hui
authors.initials: CH
authors.lastname: Deng
authors.forename: Yin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Lin
authors.initials: L
authors.lastname: Su
authors.forename: Shun-Nian
authors.initials: SN
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004381:Duodenal Ulcer / Q000150:complications; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy*; D004945:Esophagoscopy; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications*; D015552:Injections, Intralesional; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012008:Recurrence; D012086:Reoperation; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D015911:Sclerotherapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols